
PATENT COOPERATION TREATY

To:					PCT			
					WRITTEN OPINION OF THE			
see form PCT/ISA/220					INTERNATIONAL SEARCHING AUTHORITY			
			•			(PCT R	ule 43 <i>bis</i> .1)	
					Data of mailing			
					Date of mailing (day/month/year) see form PC	CT/ISA/210 (second sh	eet)
Applicant's or agent's file reference				FOR FURTHER ACTION				
	form PCT/ISA/22	_			See paragraph 2 below			
	national application N	lo.	International filing	g date (day/month/year)	<u> </u>	i date <i>(day/monthlyear</i> 3.2005)
		isination (IBC) or	noth national class	ification	and IPC			
Interr INV	national Patent Class . C07D405/06 C0)7D405/14 C0	7D211/34 C07)471 <i>/</i> 0	4 C07D401/04	A61K31/454	A61P31/18	
Appli								
PFI	ZER, INC.							
			,		• • • • • • • • • • • • • • • • • • •			
1.	This opinion co	ntains indicati	ons relating to	the fol	lowing items:	•		
	⊠ Box No. I	Basis of the op	oinion			•	·	
	☐ Box No. II	Priority						
	☑ Box No. III	Non-establish	ment of opinion v	vith reg	jard to novelty, ir	ventive step	and industrial applic	ability
	☐ Box No. IV	Lack of unity of	f invention					
	☑ Box No. V	Reasoned state	tement under Ru itations and expl	ile 43 <i>b.</i> anatior	is.1(a)(i) with reg as supporting suc	ard to novelty th statement	, inventive step or i	ndustrial
	☐ Box No. VI	Certain docum	ents cited					
	Box No. VII	Certain defect	s in the internation	onal ap	plication		•	
	🗵 Box No. VIII	Certain obser	vations on the int	ternatio	onal application			
2.	FURTHER ACTI	ION	•		•			
	written opinion of the applicant cho International Bur will not be so co	of the Internation coses an Autho reau under Rule nsidered.	nal Preliminary E rity other than the 66.1 <i>bis</i> (b) that v	xamini is one written	to be the IPEA at opinions of this I	nd the chose International S	y be considered to be nat this does not appended to the second of the se	he
	- 1 - 12 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1	EA a written rep mailing of Form	Ju togothar Wha	ra anni	moriate with alti-	enuments, ve	he applicant is invite fore the expiration of rom the priority date	3, O 10 10
	For further optio	ns, see Form P	CT/ISA/220.					
3.	For further detai	ils, see notes to	Form PCT/ISA/2	20.				
	•	•						
N) = -	ne and mailing addre	ess of the ISA		Date of	completion of	Authorized C	Officer	Aus Pelenia.
1491				this opi	nion			Lycothu 11
I	3	Patent Office - P	.B. 5818 Patentlaa	IR2 for		Diederen,	1	· (0)



WRITTEN OPINION OF THE INTERNATIONAL SEARCHING AUTHORITY

International application No. PCT/IB2006/000876

			··
	Вох	No.	I Basis of the opinion
1.	With	reg	ard to the language, this opinion has been established on the basis of:
		the i	international application in the language in which it was filed
		a tra	anslation of the international application into , which is the language of a translation furnished for the boses of international search (Rules 12.3(a) and 23.1 (b)).
2.	With nece	reg essa	ard to any nucleotide and/or amino acid sequence disclosed in the international application and ry to the claimed invention, this opinion has been established on the basis of:
	a. ty	pe o	of material:
		⊐ a	a sequence listing
] t	able(s) related to the sequence listing
	b. fo	orma	t of material:
-] (on paper
] i	in electronic form
	c. tir	me c	of filing/furnishing:
	Ε	_	contained in the international application as filed.
			filed together with the international application in electronic form.
	נ		furnished subsequently to this Authority for the purposes of search.
3	. 🗆	has	addition, in the case that more than one version or copy of a sequence listing and/or table relating thereto s been filed or furnished, the required statements that the information in the subsequent or additional pies is identical to that in the application as filed or does not go beyond the application as filed, as propriate, were furnished.
4	. Add	ditior	nal comments:

WRITTEN OPINION OF THE INTERNATIONAL SEARCHING AUTHORITY

International application No. PCT/IB2006/000876

		No. III Non-establishment of opinion with regard to novelty, inventive step and industrial licability
	The obv	questions whether the claimed invention appears to be novel, to involve an inventive step (to be non ious), or to be industrially applicable have not been examined in respect of
		the entire international application
	\boxtimes	claims Nos. 11-14
	bec	ause:
	\boxtimes	the said international application, or the said claims Nos. 11-14 (with respect to industrial application) relate to the following subject matter which does not require an international search (specify):
		see separate sheet
•		the description, claims or drawings (indicate particular elements below) or said claims Nos. are so unclear that no meaningful opinion could be formed (specify):
		the claims, or said claims Nos. are so inadequately supported by the description that no meaningful opinion could be formed (specify):
		no international search report has been established for the whole application or for said claims Nos.
		a meaningful opinion could not be formed without the sequence listing; the applicant did not, within the prescribed time limit:
		In furnish a sequence listing on paper complying with the standard provided for in Annex C of the Administrative Instructions, and such listing was not available to the International Searching Authority in a form and manner acceptable to it.
		furnish a sequence listing in electronic form complying with the standard provided for in Annex C of the Administrative Instructions, and such listing was not available to the International Searching Authority in a form and manner acceptable to it.
	٠	□ pay the required late furnishing fee for the furnishing of a sequence listing in response to an invitation under Rules 13 ter. 1(a) or (b).
		a meaningful opinion could not be formed without the tables related to the sequence listings; the applicant did not, within the prescribed time limit, furnish such tables in electronic form complying with the technical requirements provided for in Annex C-bis of the Administrative Instructions, and such tables were not available to the International Searching Authority in a form and manner acceptable to it.
		the tables related to the nucleotide and/or amino acid sequence listing, if in electronic form only, do not comply with the technical requirements provided for in Annex C-bis of the Administrative Instructions.
		See Supplemental Box for further details

Box No. V Reasoned statement under Rule 43bis.1(a)(i) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

1. Statement

Novelty (N)

Yes: Claims

1,2,4,5,7-15

No: Claims

3,6

Inventive step (IS)

Yes: Claims

1,2,4,5,7-15

Claims No:

3,6

Industrial applicability (IA)

Yes: Claims

1-10,15

Claims No:

2. Citations and explanations

see separate sheet

Box No. VIII Certain observations on the international application

The following observations on the clarity of the claims, description, and drawings or on the question whether the claims are fully supported by the description, are made:

see separate sheet

PCT/IB2006/000876

Re Item III

V

Non-establishment of opinion with regard to novelty, inventive step and industrial applicability

Claims 11-14 relate to subject-matter considered by this Authority to be covered by the provisions of Rule 67.1(iv) PCT. Consequently, no opinion will be formulated with respect to the industrial applicability of the subject-matter of these claims (Article 34(4)(a)(I) PCT).

Re Item V

Reasoned statement with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

Reference is made to the following document:

D1: WO 90/05133 A (PFIZER LIMITED; PFIZER INC) 17 May 1990 (1990-05-17)

D2: WO 03/030898 A (MERCK & CO., INC; KIM, RONALD, M; CHANG, JIANG;

CHAPMAN, KEVIN, T; MIL) 17 April 2003 (2003-04-17)

Document D1 discloses in examples 1-13 and 23 compounds which are novelty destroying for claim 6 of the present application. Examples 14-21 show examples which are novelty destroying for claim 3. Claims 3 and 6 are therefore not novel with respect to Article 33(2) PCT and can therefore also not be considered inventive according to Article 33(3) PCT.

Document D2 discloses piperidine comprising compounds for use in the treatment of HIV. This disclosure is considered to represent the closest prior art. The difference of the compounds of document D2 is enormous. The problem to be solved by the applicant was to provide alternative compounds for the treatment of HIV. Starting from document D2, a skilled person would not come to the solution of the present application as he would have to change the compounds of D2 completely. He would not have an incentive in the prior art to do so. It is therefore considered that the subject-matter of the present application, in as far it comprises novel subject-matter (claims 1,2,4,5,7-15), is inventive with respect to Article 33(3) PCT.

PCT/IB2006/000876

Re Item VIII

Certain observations on the international application

In the present set of claims, definitions for e.g. alkyl are given in the description which are not common to a person skilled in the art. Alkyl can mean a cyclic structure for example. This renders the scope of the entire application unclear for a person skilled in the art.

Claim 2 refers to an embodiment wherein a radical R3 is mentioned. There is however no definition given for said R3. This renders the scope of claim 2 unclear.